Vivus ED drug passes its second late-stage test

Shares of Vivus (VVUS) were buoyed this morning by the upbeat assessment of a second round of late-stage data on its erectile dysfunction drug avanafil. Two doses of the drug spurred statistically significant improvements in erectile function and intercourse within 15 minutes of dosing among men with diabetes. "This is the second Phase III study in which avanafil demonstrated efficacy, fast onset-of-action and was well tolerated," said Vivus Chief Executive Leland Wilson. Wilson added that ED...